Kumagai Naoki, O'Neil John J, Barth Rolf N, LaMattina John C, Utsugi Ryu, Moran Shannon G, Yamamoto Shin, Vagefi Parsia A, Kitamura Hiroshi, Kamano Chisako, Sachs David H, Yamada Kazuhiko
Transplantation Biology Research Center, Massachusetts General Hospital, Boston, MA 02129, USA.
Transplantation. 2002 Nov 15;74(9):1223-30. doi: 10.1097/00007890-200211150-00005.
Whereas clinical pancreatic transplantation has been highly successful in correcting the hyperglycemia of insulin-dependent diabetes mellitus (type 1), the results of islet transplantation have been disappointing. This discrepancy may be because of, at least in part, nonspecific loss of islets during the time required for revascularization. To test this hypothesis, we have designed composite kidney grafts containing vascularized autologous islets that can be used to compare the engraftment potential of vascularized versus nonvascularized islet tissue.
(1) Islet-cell isolation: miniature swine underwent either partial pancreatectomy to isolate autologous islets or total pancreatectomy to isolate minor antigen-mismatched islets. Islets were purified from excised pancreatic tissue by enzymatic digestion and discontinuous density gradient purification. Isolated islets were cultured for 3 days before transplant. (2) Creation of vascularized islet kidneys (IK): autologous islets alone (n=6), minor-mismatched islets alone (n=3), and minor-mismatched islets plus simultaneous autologous thymic tissue (n=3) were transplanted beneath the renal capsule of juvenile miniature swine. Minor antigen-mismatched islets were also transplanted into both the vascularized thymic graft of a thymokidney (to produce a thymo-islet kidney [TIK]) and the contralateral native kidney (n=3) and both the host thymus and beneath the renal capsule (n=2). All recipients receiving minor-mismatched islets were treated with a 12-day intravenous (IV) course of either cyclosporine A (CsA) at 10 mg/kg per day or FK506 at 0.15 mg/kg per day. (3) Assessment of Function: to evaluate the function of the transplanted islets, three animals bearing TIK and IK underwent total pancreatectomy 3 months following islet transplantation.
(1) Islet-cell yields: an average of 254,960+/-51,879 (4,452+/-932 islet equivalents [IEQ]/gram of pancreas) and 374,410+/-9,548 (4,183+/-721 IEQ/gram of pancreas) viable islets were obtained by partial pancreatectomy and complete pancreatectomy, respectively. (2) Creation of IK: autologous islets engrafted indefinitely, whereas recipients of minor-mismatched islets alone rejected the islets within 2 months. However, when minor-mismatched islets were implanted into both the thymokidney and the contralateral kidney of animals bearing a thymokidney, the islets engrafted indefinitely in both sites (>3 months). Simultaneous implantation of islets into the host thymus and under the renal capsule also led to permanent engraftment of minor-mismatched islets. (3) Function of vascularized islets: three animals with both a TIK and an IK in place for 3 months underwent total pancreatectomy. All three animals maintained normoglycemia thereafter. In two of these animals, the IKs were removed 2 months after the pancreatectomy, and in both cases normoglycemia was maintained thereafter by the TIK.
The implantation of islets beneath the autologous renal capsule permitted the establishment of a vascular supply and thereby supported normal islet-cell growth and function. The presence of thymic tissue beneath the autologous renal capsule facilitated the engraftment of minor-mismatched islets, and such grafts achieved results similar to autologous islet transplants. Therefore, the ability to create vascularized islet grafts may provide a strategy for successful islet transplantation across allogeneic and potentially across xenogeneic barriers.
尽管临床胰腺移植在纠正胰岛素依赖型糖尿病(1型)的高血糖方面非常成功,但胰岛移植的结果却令人失望。这种差异可能至少部分是由于在血管重建所需的时间内胰岛发生非特异性丢失。为了验证这一假设,我们设计了包含血管化自体胰岛的复合肾移植,可用于比较血管化胰岛组织与非血管化胰岛组织的植入潜力。
(1)胰岛细胞分离:小型猪接受部分胰腺切除术以分离自体胰岛或全胰腺切除术以分离次要抗原不匹配的胰岛。通过酶消化和不连续密度梯度纯化从切除的胰腺组织中纯化胰岛。分离的胰岛在移植前培养3天。(2)创建血管化胰岛肾(IK):将单独的自体胰岛(n = 6)、单独的次要不匹配胰岛(n = 3)以及次要不匹配胰岛加同时植入的自体胸腺组织(n = 3)移植到幼年小型猪的肾包膜下。次要抗原不匹配的胰岛也被移植到胸腺肾的血管化胸腺移植物中(以产生胸腺 - 胰岛肾[TIK])和对侧天然肾(n = 3)以及宿主胸腺和肾包膜下(n = 2)。所有接受次要不匹配胰岛的受体接受为期12天的静脉内(IV)疗程,每天给予10 mg/kg的环孢素A(CsA)或0.15 mg/kg的FK506。(3)功能评估:为了评估移植胰岛的功能,三只带有TIK和IK的动物在胰岛移植后3个月接受全胰腺切除术。
(1)胰岛细胞产量:通过部分胰腺切除术和全胰腺切除术分别获得平均254,960±51,879(4,452±932胰岛当量[IEQ]/克胰腺)和374,410±9,548(4,183±721 IEQ/克胰腺)个存活胰岛。(2)IK的创建:自体胰岛无限期植入,而仅接受次要不匹配胰岛的受体在2个月内排斥胰岛。然而,当次要不匹配胰岛植入到带有胸腺肾的动物的胸腺肾和对侧肾中时,胰岛在两个部位均无限期植入(> 3个月)。将胰岛同时植入宿主胸腺和肾包膜下也导致次要不匹配胰岛的永久植入。(3)血管化胰岛的功能:三只同时拥有TIK和IK且已存在3个月的动物接受全胰腺切除术。此后所有三只动物均维持正常血糖。在其中两只动物中,胰腺切除术后2个月切除IK,在这两种情况下,TIK此后均维持正常血糖。
将胰岛植入自体肾包膜下可建立血管供应,从而支持正常胰岛细胞的生长和功能。自体肾包膜下存在胸腺组织促进了次要不匹配胰岛的植入,并且这种移植物取得了与自体胰岛移植相似的结果。因此,创建血管化胰岛移植物的能力可能为成功进行同种异体甚至可能的异种胰岛移植提供一种策略。